Harvard Biosci Stock Price, News & Analysis

Harvard Bioscience (Nasdaq: HBIO) will release its financial results for Q2 2021 on August 5, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. ET, accessible via toll-free number 1 (877) 303-7611 or international number 1 (970) 315-0445, with conference ID # 6293853. The call will also be webcast through the Harvard Bioscience website. The results and accompanying slide presentation will be available on the Investor Relations section of their site.

Harvard Bioscience (Nasdaq: HBIO) reported a revenue increase of 14% for Q1 2021, totaling $27 million, driven by strong pre-clinical product demand which rose 24%. This growth follows continued momentum from Q4 2020, aided by effective sales strategies and improved academic lab sales. The operating loss improved significantly, with adjusted operating income reaching $3.2 million and an adjusted operating margin of 12%. The company expects revenue growth of 10% to 14% for 2021, indicating a positive outlook for future business performance.

Harvard Bioscience (Nasdaq: HBIO) will announce its Q1 2021 financial results on May 6, 2021, before market opening. A conference call will follow at 8:00 a.m. ET for discussions on the earnings report. Investors can participate by calling toll-free 1 (877) 303-7611 or internationally at 1 (970) 315-0445, using conference ID # 5876756. The call will also be available via webcast on Harvard Bioscience's website. The company specializes in technologies and products for research and drug development, serving a global client base.

Harvard Bioscience reported Q4 2020 revenue of $31.0 million, returning to pre-COVID levels, aided by a 19% year-over-year increase in preclinical product revenue. Operating income rose to $2.8 million, with a GAAP operating margin of 8.9%. The company successfully refinanced its credit facility, expected to save approximately $3 million annually in interest. For 2021, Harvard anticipates revenue growth of 8% to 12% and adjusted operating margins in the mid-to-upper teens, driven by new products and improved profit mix.

Harvard Bioscience (Nasdaq: HBIO) will release its fourth-quarter financial results for the period ending December 31, 2020, before the market opens on March 10, 2021. A conference call will be held that same day at 8:00 a.m. Eastern Time to discuss the results, accessible via toll-free and international numbers. The call will also be available through a live webcast on the company's website, where financial information including the earnings release and presentation slides will be published.

Harvard Bioscience (Nasdaq: HBIO) has successfully closed a new $65 million credit facility, refinancing existing debt to enhance liquidity and reduce borrowing costs. This refinancing will yield over $2 million in annual cash interest savings starting in 2021 while providing greater operational flexibility through less restrictive covenants. The facility includes a $40 million term loan and a $25 million senior revolving credit line, aimed at supporting the company's transition into a profitable growth platform.

Harvard Bioscience (Nasdaq: HBIO) will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference on November 18, 2020. CEO Jim Green and CFO Michael Rossi will engage in virtual meetings throughout the day. Interested investors can schedule a meeting by contacting their Benchmark representative or directly reaching out to Vince Curatola. Presentation materials will be available on the company’s investor relations page that same day at 8:00 AM ET. Harvard Bioscience specializes in technologies for drug development and serves a wide range of global customers.

Harvard Bioscience (Nasdaq: HBIO) reported Q3 2020 financial results showing improved operating income and reduced net debt year-over-year. Revenue rose sequentially to $24.0 million, supported by demand from CRO/pharma and the reopening of academic labs. Adjusted operating income was $3.6 million, with an operating margin of 14.8%. The company anticipates continued growth, forecasting mid to upper teen operating margins for the second half of 2020, driven by disciplined cost management and targeted investments.

Harvard Bioscience (Nasdaq: HBIO) will release its Q3 financial results for the period ended September 30, 2020 before the market opens on November 5, 2020. A conference call to discuss these results will take place on the same day at 8:00 a.m. ET. Participants can join the call via toll-free dial-in or access the live webcast on the company’s website. Financial information and related materials will be available in the Investor Relations section of the site.